Bausch Health Companies Inc. (NYSE:BHC) Shares Sold by CastleKnight Management LP

CastleKnight Management LP trimmed its holdings in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 44.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 98,300 shares of the company's stock after selling 77,400 shares during the quarter. CastleKnight Management LP's holdings in Bausch Health Companies were worth $792,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BHC. JPMorgan Chase & Co. boosted its holdings in Bausch Health Companies by 1,246.0% during the fourth quarter. JPMorgan Chase & Co. now owns 19,840 shares of the company's stock worth $160,000 after buying an additional 18,366 shares in the last quarter. SG Americas Securities LLC increased its stake in Bausch Health Companies by 62.0% during the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock worth $26,614,000 after buying an additional 1,263,706 shares in the last quarter. Range Financial Group LLC acquired a new position in shares of Bausch Health Companies during the fourth quarter valued at approximately $1,004,000. Vanguard Group Inc. lifted its position in shares of Bausch Health Companies by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company's stock valued at $94,460,000 after acquiring an additional 145,078 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Bausch Health Companies in the fourth quarter worth approximately $180,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Trading Down 3.2 %

Bausch Health Companies stock traded down $0.15 during mid-day trading on Friday, hitting $4.55. The company's stock had a trading volume of 1,724,544 shares, compared to its average volume of 2,637,343. The stock's fifty day moving average is $5.79 and its two-hundred day moving average is $7.10. The firm has a market capitalization of $1.65 billion, a PE ratio of -37.91, a price-to-earnings-growth ratio of 0.37 and a beta of 0.34. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $9.85.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The business had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. On average, equities analysts expect that Bausch Health Companies Inc. will post 4.41 EPS for the current fiscal year.

Analysts Set New Price Targets

BHC has been the subject of a number of research reports. Royal Bank of Canada upped their target price on shares of Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a report on Friday, May 2nd. StockNews.com raised shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Thursday, May 1st. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, Bausch Health Companies currently has an average rating of "Hold" and an average target price of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.